Propanc Biopharma

Propanc Biopharma, Inc. was formed in Melbourne in October 2007 and has its principal office in Camberwell, Victoria. It describes itself as a development-stage company focused on treatments for pancreatic, ovarian and colorectal cancer. Its lead candidate PRP combines the pancreatic proenzymes trypsinogen and chymotrypsinogen. The FDA granted PRP orphan drug designation for pancreatic cancer in June 2017; the company has prepared assays and bought raw materials for a first-in-human phase 1b study in advanced cancer, and is developing a synthetic recombinant version with the Universities of Jaén and Granada.